Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-04
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
OLIG2 Phosphorylation Modulates Glioma Invasion via TGF-β Pa
2026-07-03
This study reveals that post-translational modifications of OLIG2, a CNS-specific transcription factor, act as a molecular switch between proliferation and invasion in glioblastoma by modulating TGF-β2 signaling. The findings highlight new therapeutic strategies targeting OLIG2 phosphorylation and TGF-β pathway to restrict glioma invasiveness.
-
Myriocin in Targeted Sphingolipid Metabolism: Pathways and P
2026-07-03
Explore how Myriocin, a potent serine palmitoyltransferase inhibitor, drives innovation in sphingolipid metabolism research and cancer cell cycle modulation. This article uniquely bridges mechanistic insights and practical protocols for advanced biomedical studies.
-
Applied Use-Cases of Olaparib (AZD2281) in DNA Damage Resear
2026-07-02
Olaparib (AZD2281) is transforming DNA damage response and cancer research by enabling precision-targeted inhibition of PARP1/2, especially in BRCA-deficient models. This guide details advanced experimental workflows, troubleshooting insights, and the integration of phase-separation biology to elevate your assay design.
-
A-1331852 (SKU B6164): Reliable BCL-XL Inhibition in Apoptos
2026-07-02
This article explores how A-1331852 (SKU B6164), a potent and selective BCL-XL inhibitor, addresses persistent challenges in apoptosis and cytotoxicity assays. Drawing on validated protocols, peer-reviewed data, and real-world lab scenarios, it demonstrates the compound’s value in reproducibility and sensitivity for apoptosis research.
-
Partial BACE1 Inhibition: Synaptic Safety in Amyloid Beta Re
2026-07-01
Satir et al. (2020) demonstrate that moderate inhibition of BACE1, leading to up to 50% amyloid beta reduction, does not impair synaptic transmission in cultured neurons. This finding informs optimal dosing strategies for BACE inhibitors in Alzheimer’s disease research, balancing efficacy with neuronal safety.
-
Bile Acid Metabolism Subtypes Mark Immune Dysfunction in CRC
2026-07-01
Feng et al. (2026) introduce an integrative subtyping of colorectal cancer based on bile acid metabolism, identifying CLCA1, UGT2A3, and ZG16 as key markers of immune dysfunction and poor prognosis. Their approach refines our understanding of the tumor immune microenvironment and offers new perspectives for biomarker-driven stratification in CRC.
-
NAD+, AMPK, and Autophagy: Strategic Insights for Translatio
2026-06-30
Explore how Nicotinamide Adenine Dinucleotide (NAD+) and AMPK signaling reframe our understanding of cellular energy stress, metabolic adaptation, and experimental protocol design. This article synthesizes mechanistic discoveries with actionable translational guidance, leveraging APExBIO’s high-purity NAD+ and challenging prevailing dogmas in autophagy regulation.
-
NU7441 (KU-57788): Precision DNA-PK Inhibition in Oncology A
2026-06-30
Explore NU7441 (KU-57788), a potent DNA-PK inhibitor, and its pivotal role in advanced DNA repair and oncology research. This article uniquely analyzes selectivity, assay considerations, and translational impact, building on cutting-edge pharmacologic insights.
-
Phosphatase Inhibitor Cocktail 3: Precision in Signalomics
2026-06-29
Explore how Phosphatase Inhibitor Cocktail 3 (100X in DMSO) elevates phosphoprotein analysis with robust serine/threonine phosphatase inhibition. This article reveals innovative protocol optimizations and new insights into preserving protein phosphorylation dynamics for advanced signalomics research.
-
IWR-1-endo: Wnt Signaling Inhibitor Workflows and Optimizati
2026-06-29
IWR-1-endo is a potent Wnt signaling inhibitor, enabling high-precision modulation of the Wnt/β-catenin pathway in applications ranging from colorectal cancer research to regenerative biology. This guide delivers experimentally-backed workflows, troubleshooting strategies, and comparative insights to maximize reproducibility and data quality in Wnt pathway inhibition assays.
-
Nicotinamide Adenine Dinucleotide (NAD+): Unraveling Energet
2026-06-28
Explore how Nicotinamide Adenine Dinucleotide (NAD+) orchestrates cellular energy management and autophagy inhibition, with new insights from recent AMPK research. This cornerstone piece offers advanced guidance for metabolic signaling assays and practical protocols beyond existing NAD+ content.
-
Biotin-HPDP: Mechanistic Insight and Strategic Value in Tran
2026-06-27
This thought-leadership article explores how Biotin-HPDP (N-[6-(biotinamido)hexyl]-3’-(2’-pyridyldithio)propionamide) uniquely empowers translational researchers to interrogate and manipulate thiol-specific post-translational modifications, with a special emphasis on S-nitrosylation in plant aluminum resistance. By weaving together recent mechanistic breakthroughs and practical workflow optimization, we offer strategic guidance for maximizing the reagent’s impact in redox biology and beyond.
-
ETS1 Regulates Mitophagy via SENP2/HSPA8/FUNDC1 in BPD Model
2026-06-26
This study reveals that ETS1 inhibits mitochondrial damage-induced mitophagy by targeting the SENP2/HSPA8/FUNDC1 axis, offering new mechanistic insight into the molecular regulation of bronchopulmonary dysplasia (BPD). These findings highlight ETS1 as a potential therapeutic target for preserving lung development in neonatal disease models.
-
Alosetron in Intestinal Stem Cell Fate: Beyond 5-HT3 Antagon
2026-06-26
Explore Alosetron as a selective 5-HT3 receptor antagonist and its advanced applications in dissecting intestinal stem cell fate and epithelial homeostasis. This article delivers a unique, mechanistic perspective linking serotonin receptor pharmacology to CDC42-YAP-mTOR signaling.
-
2,2,2-Trichloroethanol: A Small Molecule Biochemical for Adv
2026-06-25
2,2,2-Trichloroethanol is redefining protein analysis workflows, offering unmatched versatility as a small molecule biochemical reagent in both classical and emerging molecular biology research. By streamlining protein visualization and modification, it enables reproducible, high-sensitivity assays that directly accelerate discovery in neurodegenerative and signal transduction studies.